净利润超35亿元刷新历史最好成绩，华东医药押注了哪些领域

Core Insights - East China Pharmaceutical achieved a record annual performance in 2024 with revenue of 41.906 billion yuan, a growth rate of 3.16%, and a net profit of 3.512 billion yuan, reflecting a double-digit growth of 23.72% [1] - The company successfully met the performance targets set in the 2022 restricted stock incentive plan for 2024 [1] Revenue Structure - The core subsidiary, Sinopharm East China, contributed sales revenue of 13.811 billion yuan, a year-on-year increase of 13.05%, and a net profit of 2.876 billion yuan, up 29.04% [2] - The pharmaceutical commercial segment generated revenue of 27.092 billion yuan, a slight increase of 0.41%, with a net profit of 456 million yuan, up 5.58% [2] - The medical aesthetics segment saw revenue of 2.326 billion yuan, a decline of 4.94% due to slowing consumer demand [2] - The industrial microbiology segment achieved sales revenue of 711 million yuan, a significant growth of 43.12% [2] Dividend Announcement - East China Pharmaceutical announced a cash dividend of 1.017 billion yuan for 2024, along with an interim dividend of 614 million yuan, totaling an expected cash dividend of 1.631 billion yuan for the year [2] Innovation Pipeline - The company’s innovative product pipeline has entered the acceptance phase, with over 80 projects currently in development [4][5] - The ADC new drug for treating platinum-resistant ovarian cancer received conditional approval from the NMPA in November 2024 [5] - The company has established a robust ADC pipeline with over 12 projects through a combination of in-house development and external partnerships [5] Product Approvals - The ovarian cancer drug Senapali capsules received NMPA approval in January 2025 [6] - The CAR-T product Zevokioran injection has completed certification for over 200 domestic medical institutions since its approval in March 2024 [6] - The innovative self-immune product Arcalyst for rare diseases received approval in 2024 [6] Medical Aesthetics Performance - The medical aesthetics segment generated revenue of 2.326 billion yuan, reflecting a decline amid economic challenges [10] - The subsidiary Sinclair in the UK reported a revenue drop of 25.81% to approximately 967 million yuan [10] - The domestic subsidiary Xinkeli achieved revenue of 1.139 billion yuan, a growth of 8.32% [11] Product Development in Medical Aesthetics - The company has launched 40 high-end medical aesthetic products, with 26 already on the market [11] - New products such as Ellansé have been introduced, with significant uptake in high-end medical institutions [11] - The energy source device V20 received NMPA approval in September 2024, with over 200 institutions adopting the technology [12]